Lead program TG4050 (individualized immunotherapy): – First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized ...
Tennessee’s defense came to play against the Oklahoma Sooners. The Vols played on the road in their first in-conference game of the season and won 25-15.